Drug Discovery World

APRIL 19, 2024

News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer. The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s.

Gene Therapy 52

Gene Therapy Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

APRIL 5, 2024

News round-up for 1-5 April by DDW Digital Content Editor Diana Spencer. R&D partnership to jointly develop new ALS drugs PrecisionLife and the Nucleic Acid Therapy Accelerator (NATA) have announced a collaboration to co-develop novel oligonucleotide therapies for sporadic motor neurone disease/ALS.

Drugs 52

Drugs Life Science Development Research 52

Drug Discovery World

APRIL 22, 2024

The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Drug Discovery World

MARCH 14, 2024

NeuroSense Therapeutics has reported additional positive data from its six-month double-blind Phase IIb PARADIGM trial of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The PARADIGM trial’s secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival.

Trials 52

Trials Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

APRIL 22, 2024

The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Drug Discovery World

MARCH 15, 2024

News round-up for 11-15 March by DDW Digital Content Editor Diana Spencer. The top stories: New drug shows promising neuroprotective effects Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD).

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

BioSpace

JUNE 2, 2022

Amylyx Pharmaceuticals shared news that the FDA has extended the review period for AMX0035, a combination drug treatment with the potential to treat patients with ALS.

Drugs 71

Drugs 71

pharmaphorum

SEPTEMBER 30, 2022

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug. — The ALS Association (@alsassociation) September 29, 2022. .

Drugs 82

Drugs Doctors Doctor FDA Approval 82

STAT News

MARCH 23, 2023

How do you know when an ALS treatment is working? We also talk about the latest news in the life sciences, including Regeneron Pharmaceuticals’ latest data for its powerhouse drug Dupixent, an about-face for Sarepta Therapeutics, and how the FDA appears to view biomarkers in neurological diseases. Bernie Sanders.

Life Science 98

Life Science Drugs Gene Therapy Gene 98

Camargo

SEPTEMBER 8, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. In the News: August 2021 Regulatory and Development Updates. In the News: July 2021 Regulatory and Development Updates.

Development 186

Development Regulation Production Drugs 186

pharmaphorum

OCTOBER 3, 2022

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 per year in the US, sparking outcry. ALS affects over 30,000 people in the US.

Drugs 52

Drugs Generic Drugs FDA Approval Trials 52

XTalks

SEPTEMBER 17, 2021

The ALS Association is pushing for rapid FDA approval of Amylyx Pharmaceuticals Inc.’s s candidate drug AMX0035 (sodium phenylbutyrate/taurursodiol) for the treatment of amyotrophic lateral sclerosis, or ALS. This time, the group is backing a drug that they believe will greatly benefit ALS patients.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

Drug Discovery World

AUGUST 25, 2023

News round-up for 21-25 August by DDW Digital Content Editor Diana Spencer. Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia.

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

Drug Discovery World

APRIL 11, 2023

13 Official comment Professor David Jackson, Professor of Respiratory Medicine and Clinical Lead for Guy’s & St Thomas’ Asthma Service, said: “Today’s NICE recommendation is excellent news for our patients. Wenzel S, et al. Chung KF, et al. Godar M, et al. 2018; 10 (1): 34‐45 Duchesne M, et al. Li Y, et al.

Clinical Trials 98

Clinical Trials Clinical Trials In-Vivo Medicine 98

The Pharma Data

OCTOBER 20, 2020

Investigational Drug May Prolong Survival in Patients With ALS. 20, 2020 — Long-term survival analysis shows that patients with earlier initiation of sodium phenylbutyrate-taurursodiol (PB-TURSO) treatment for amyotrophic lateral sclerosis (ALS) have longer median overall survival, according to a study published online Oct.

Drugs 52

Drugs Trials Research 52

pharmaphorum

OCTOBER 18, 2021

Already struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral sclerosis (ALS) missed the mark in a late-stage study. The post Blow to Biogen as ALS hope tofersen flunks phase 3 trial appeared first on.

Trials 44

Trials Gene Editing Gene Gene Therapy 44

Drug Discovery World

JANUARY 20, 2023

News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies.

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

The Pharma Data

OCTOBER 16, 2020

16, 2020 — An experimental drug combination lengthens survival for patients with amyotrophic lateral sclerosis (ALS), new research shows. The new clinical trial of 137 patients with the disease, also known as Lou Gehrig’s disease, found that those who took AMX0035 lived a median of 6.5 FRIDAY, Oct.

Drugs 52

Drugs Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

JULY 31, 2023

The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter results, the company said its new ‘Fit for Growth’ programme would generate approximately $1 billion in gross operating expense savings.

FDA Approval 52

FDA Approval Production Clinical Trials Clinical Trials 52

pharmaphorum

JULY 26, 2022

Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy tofersen within six months. The rarity of SOD1-ALS means however that tofersen is unlikely to make big sales, even if it has a high price.

Drugs 44

Drugs Sales Marketing Trials 44

Drug Channels

APRIL 26, 2022

Oil up your glove, lace up your cleats, and let's run the bases around this month's news stories. Remember: Sometimes you win, sometimes you lose, and sometimes it rains.

Pharmacy 80

Pharmacy Insulin Doctors Doctor 80

Drug Discovery World

NOVEMBER 24, 2023

This extremely welcome news supports our ambition to work with NHS partners to challenge treatment expectations for patients with limited treatment options. We are passionate, determined people, working with constructive impatience to make a difference for patients.” Marcano-Bonilla L, et al. Turkes F, et al. Khan SA et al.

HR 52

HR Licensing Licensing Trials 52

Worldwide Clinical Trials

FEBRUARY 28, 2023

Though cancer ran in my family, we definitely weren’t expecting this news, and the survival rates left little to be hopeful for,” says Rob. In 2018, we partnered with Project ALS to fund research at Columbia University into synthetic motor neurons in ALS patients. To say it was devastating is an understatement.

Clinical Trials 130

Clinical Trials Clinical Trials Research Trials 130

Drug Discovery World

NOVEMBER 27, 2023

References Mistry RK, Kelsall E, Sou SN, et al. Budge JD, Knight TJ, Povey J, et al. Patel T, Ingham C, Fleming J, et al. Anis also serves on the scientific and editorial advisory board of Genetic Engineering News , Mary Ann Liebert, Inc. Biotechnol Bioeng 2012;118:2326. Metab Eng 2020;57:203.

Production 59

Production Engineer Gene Editing Gene 59

Drug Discovery World

OCTOBER 31, 2023

To date, the clinical and research-based assessment of neurodegenerative diseases such as Alzheimer’s, Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS), has relied on clinical profiles, symptoms, scoring scales such as the ALS Functional rating scale (ALSFRS), and life expectancy.

Development 59

Development Drugs Trials Clinical Trials 59

Drug Discovery World

JUNE 14, 2023

7 There could be around 9,400 new cases of ovarian cancer every year in the UK by 2038-2040, projections suggest. Guarneri V, et al. Walker M, et al. Ovarian cancer represents a significant unmet need in gynaecological cancers. AstraZeneca has a bold ambition to provide hope for patients with cancer. Gynaecol Oncol.

Gene 52

Gene Genetics DNA Research 52

Pharmaceutical Technology

JANUARY 30, 2023

The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. This is due to generally more stringent criteria on approvals in the wake of the Aduhelm scandal. However, non-NME and biosimilar approvals increased in 2022. months longer on the treatment.

Drugs 130

Drugs Manufacturing Contract Manufacturing FDA Approval 130

Delveinsight

AUGUST 24, 2021

Unpleasant news strike hard for their first deal in the rare neurodegenerative disease domain. Alexion focuses on finding medications for rare diseases and has an ongoing clinical trial for Ultomoris (Ravulizumab) to treat the rare disease – Amyotrophic Lateral Sclerosis (ALS). Gianluca Pirozzi, MD, Ph.D.,

Clinical Trials 96

Clinical Trials Clinical Trials Trials Drugs 96

pharmaphorum

SEPTEMBER 28, 2021

Biohaven is still running a phase 2/3 trial of the MPO inhibitor in amyotrophic lateral sclerosis (ALS), another neurodegenerative disease, that is due to complete enrolment later this year. The post Bad news for Biohaven as verdiperstat flunks first phase 3 test appeared first on.

Trials 57

Trials Drugs Clinical Trials Clinical Trials 57

The Pharma Data

DECEMBER 9, 2020

Laila Al-Shaar, M.P.H., More News Resources. Professional. More Plant Foods, Less Red Meat May Cut Heart Disease Risk. WEDNESDAY, Dec. 9, 2020 — Substituting high-quality plant foods such as legumes, nuts, or soy for red meat might reduce the risk for coronary heart disease (CHD), according to a study published online Dec.

HR 52

HR Protein Production Research 52

The Pharma Data

DECEMBER 18, 2020

. “The finding that the COVID-19 death rate was three times higher than for seasonal influenza is particularly striking when reminded that the 2018/2019 flu season had been the worst in the past five years in France in terms of number of deaths,” Quantin noted in a Lancet news release. ” U.S. ” U.S.

Insulin 52

Insulin Medicine Research Vaccination 52

pharmaphorum

DECEMBER 15, 2022

Despite the renewed public focus on RSV seen in the news recently, there is still a great deal of work to be done to uncover realities of RSV in the UK, especially among older populations. Tseng H, et al. Respiratory Syncytial Virus. Available at: [link] Last accessed: December 2022. Fleming, D. BMC Infectious Diseases. Childs, A.,

Scientist 67

Scientist Research Vaccination Vaccine 67

Delveinsight

FEBRUARY 4, 2021

The news comes three months after Bristol Myers reported a similar performance in the 666-patient POETYK PSO-1 study, in which deucravacitinib also outperformed placebo and Otezla. Prothena brings AL amyloidosis drug back to the clinic. The company displayed broad strokes with plans to show complete data at a future medical meeting.

Trials 52

Trials Drugs Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 17, 2021

i Criner GJ, Delage A, Voelker K, et al., “Improving lung function in severe heterogenous emphysema with the Spiration® Valve System (EMPROVE): a multicenter, open-label, randomized, controlled trial,” American Journal of Respiratory and Critical Care Medicine, vol. ii Schuhmann M, Raffy P, Yi Y, et al.

Medicine 52

Medicine Life Science Trials Clinical Trials 52

FDA Law Blog

FEBRUARY 27, 2023

This error has appeared not just in articles and other news publications but in some court documents as well. al , Case No. Gilbert — One misnomer that has been repeated over the years has been the reference to the “Drug Enforcement Administration” (“DEA”) as the “Drug Enforcement Agency.” The DEA has even made the same mistake.

Pharmacy 45

Pharmacy Drugs Regulation Manufacturing 45

pharmaphorum

MAY 11, 2021

“This is great news for the aHUS community in Scotland, as ravulizumab will reduce the number of infusions needed per year, significantly improving the quality of life for all those living with the condition,” according to David Kavanagh, professor of complement therapeutics at the NRCTC. May’s other decisions.

Medicine 52

Medicine Sales Drugs Trials 52

The Pharma Data

NOVEMBER 17, 2021

AstraZeneca news release: AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK [link] [Last accessed: November 2021] 2. Burn, E et al, Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis. Available at: [link] [Accessed August 2021] 6.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52